Allied Market Research
image  Direct : +1 (617) 674-4143 | Toll Free : +1 (855) 711-1555


Report Image
In Vitro Fertilization Market in Asia Pacific - Country Analysis by End Users (Clinics, Hospitals, Surgical Centers, Clinical Research Institutes, Banks) Number of Cycles, Revenue, Market Share, Growth, Trends, and Forecast Through 2020
Published: March-2014    |    Formats: PDF & Excel   |   Author(s):Debbie Shields   |   Code: ME 14186
  • Report
    Overview
  • Table of
    Contents
  • Research
    Methodology
  • Analyst's
    Review
  • Sample

Pages 105
Tables 69

The advancement of IVF market in Asia Pacific is characterized by major factors such as the rising standards of living and growing number of couples delaying parenthood due to professional and financial commitments. The Asia Pacific IVF market, valued at $1.3 billion in 2012, is estimated to reach $4.2 billion by 2020. As the chances of conceiving lowers with age, delayed pregnancy in women is one of the major driving factors of the IVF market. The success rate of getting pregnant with IVF technique is higher within the age group of 35-39. Other driving factors of the IVF market are rise in infertility rates due to rise in stress levels, change in life style and fertility related diseases.

Asia, in particular is facing the challenge of aging population and lower work force replacement. These trends would impact the socio-economic development and progress. Many countries in Asia Pacific region such as Japan, North and South Korea, China, Vietnam, Singapore and Thailand have fertility rates that are way below the replacement fertility levels. According to the East West center study, countries such as Japan, South Korea, Singapore, Taiwan, etc., Asia’s prosperous economies have the lowest birth rate worldwide.

Taiwan has the lowest birth per women which is 0.91 (2010) when compared with South Korea (1.15), Japan (1.39) and Singapore (1.16). This trend is due to couples postponing parenthood, couples preferring few children or rather no children at all.

Countries in Asia Pacific with such lower levels of fertility have initiated innovative assistance programs to promote parenthood and provide subsidies on fertility treatments such as IVF. In addition, lower treatment cost as compared to western countries has also proved to be positive for the artificial reproductive treatment (ART) industry in the region. With the advancing technologies, the success ratio of ART, especially IVF, has also grown in the region. Together, these factors have not only provided the region with an opportunity to improve on its birth rates, but also have added to the growth of the medical tourism industry in the region. Due to the rising trend in Medical tourism, many countries such as Malaysia, Thailand, Singapore, and India are gaining popularity.

In Vitro Fertilization Market in Asia Pacific-Another investing platform

KEY BENEFITS

  • In-depth analysis of the IVF market in 12 major country market with a cross sectional analysis of  end users segments
  • Quantitative analysis of the current market and estimations through 2013-2020
  • Assessment and ranking of the factors affecting the global market and impact analysis of the same
  • Analysis of trends in various geographic segments that would help the companies to plan their strategies depending on the region

COVERAGE

For the purpose of better understanding of the market, the report has covered 12 country markets and has presented a cross sectional analysis of each country market for end user segments. Both revenue and number of IVF cycles performed at various end use segments is calculated based on various indicators, authentic secondary sources, government publications and primary research with leading IVF providers in each of the country. The qualitative analysis is carried out for each country market for major trends and market dynamics. The major countries covered in this study include:

  • India
  • China
  • Japan
  • Vietnam
  • Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Indonesia
  • Philippines
  • Singapore

Each of these country markets has been analyzed for following end user segments:

  • Hospitals
  • Clinics
  • Surgical Centers
  • Research institutes
  • Banks

Apart from that, profiles of major market player in each of the country have also been provided for better understanding of market strategy and competitive scenario.


  1. REPORT OUTLINE

1.1. Report Description
1.2. Key Benefits
1.3. Coverage
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Models

2. EXECUTIVE SUMMARY

3. ASIA PACIFIC IN VITRO FERTILIZATION (IVF) MARKET (REVENUE AND NUMBER OF CYCLES)

 3.1. Overview
 3.2. IVF Pricing Trends by Country
 3.3. IVF Cycles by Country
 3.4. Drivers
 3.5. Restraints
 3.6. Opportunities

 3.7. Market by End User

3.7.1. Fertility clinics
3.7.2. Hospitals
3.7.3. Surgical centers
3.7.4. Banks
3.7.5. Clinical research institutes

3.8. Profiles of Major Players

3.8.1. Thermo Fisher Scientific Inc.

3.8.1.1. Company overview
3.8.1.2. Company snapshot
3.8.1.3. Financial overview
3.8.1.4. Market share
3.8.1.5. Strategic moves and developments

3.8.2. EMD Serono, Inc.

3.8.2.1. Company overview
3.8.2.2. Company snapshot
3.8.2.3. Financial overview
3.8.2.4. Market share
3.8.2.5. Strategic moves and developments

3.8.3. Sun Pharmaceutical

3.8.3.1. Company overview
3.8.3.2. Company snapshot
3.8.3.3. Financial overview
3.8.3.4. Market share
3.8.3.5. Strategic moves and developments

3.8.4. Cadila Healthcare Ltd.

3.8.4.1. Company overview
3.8.4.2. Company snapshot
3.8.4.3. Financial overview
3.8.4.4. Market share
3.8.4.5. Strategic moves and developments

3.8.5. LG Life Sciences.

 3.8.5.1. Company overview
3.8.5.2. Company snapshot
3.8.5.3. Financial overview
3.8.5.4. Market share
3.8.5.5. Strategic moves and developments

4. CHINA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

4.1. Number of Cycles by Hospitals/Clinics

4.2. Market by End User

4.2.1. Fertility clinics
4.2.2. Hospitals
4.2.3. Surgical centers
4.2.4. Banks
4.2.5. Clinical research institutes

4.3. Drivers
4.4. Restraints
4.5. Regulatory issues, legislations and authorities
4.6. Insurance reimbursement scenario
4.7. Profiles of Major Players (Reproductive & and genetic Hospital Citic-Xiangya, Shenyang Hospital, China, IVF Center China, Shandong Provincial Hospital, China, Centre for Reproductive Medicine China)

4.7.1. Company overview
4.7.2. Company snapshot
4.7.3. Financial overview
4.7.4. Market share
4.7.5. Strategic moves and developments

5. JAPAN IVF MARKET (REVENUE AND NUMBER OF CYCLES)

5.1. Number of Cycles by Hospitals/Clinics
5.2. Market by End User

5.2.1. Fertility clinics
5.2.2. Hospitals
5.2.3. Surgical centers
5.2.4. Banks
5.2.5. Clinical research institutes

5.3. Drivers
5.4. Restraints
5.5. Regulatory issues, legislations and authorities
5.6. Insurance reimbursement scenario
5.7. Profiles of Major Players (Hiroshima Hart Clinic, IVF Japan, The Advanced Reproductive Technological Institute (ARMT), Yoshida Ladies Clinic Reproductive ART Center, Iwaki-Women's Clinic)

5.7.1. Company overview
5.7.2. Company snapshot
5.7.3. Financial overview
5.7.4. Market share
5.7.5. Strategic moves and developments

6. KOREA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

6.1. Number of Cycles by Hospitals/Clinics
6.2. Market by End User

6.2.1. Fertility clinics
6.2.2. Hospitals
6.2.3. Surgical centers
6.2.4. Banks
6.2.5. Clinical research institutes

6.3. Regulatory issues, legislations and authorities
6.4. Insurance reimbursement scenario
6.5. Profiles of Major Players (Maria Fertility Hospital, Cha General Hospital, Seoul National University Hospital IVF Center, Dongtan Cheil Women's Clinic Ajou University)

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Financial overview
6.5.4. Market share
6.5.5. Strategic moves and developments

7. INDIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

7.1. Number of Cycles by Hospitals/Clinics
7.2. Market by End User

7.2.1. Fertility clinics
7.2.2. Hospitals
7.2.3. Surgical centers
7.2.4. Banks
7.2.5. Clinical research institutes

7.3. Regulatory issues, legislations and authorities
7.4. Insurance reimbursement scenario
7.5. Profiles of Major Players (Bourn Hall Clinic, Southend Fertility and IVF Centre, Morpheus IVF Fertility Center, Bloom Fertility Center, Manipal Ankur, Cloudnine Fertility, Nova IVI Fertility)

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Financial overview
7.5.4. Market share
7.5.5. Strategic moves and developments

8. AUSTRALIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

8.1. Number of Cycles by Hospitals/Clinics
8.2. Market by End User

8.2.1. Fertility clinics
8.2.2. Hospitals
8.2.3. Surgical centers
8.2.4. Banks
8.2.5. Clinical research institutes

8.3. Regulatory issues, legislations and authorities
8.4. Insurance reimbursement scenario
8.5. Profiles of Major Players (Virtus Health, Monash IVF, Genea Limited, City Fertility, Flindersfertility)

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Financial overview
8.5.4. Market share
8.5.5. Strategic moves and developments

9. NEW ZEALAND IVF MARKET (REVENUE AND NUMBER OF CYCLES)

9.1. Number of Cycles by Hospitals/Clinics
9.2. Market by End User

9.2.1. Fertility clinics
9.2.2. Hospitals
9.2.3. Surgical centers
9.2.4. Banks
9.2.5. Clinical research institutes

9.3. Regulatory issues, legislations and authorities
9.4. Insurance reimbursement scenario
9.5. Profiles of Major Players (Fertility Associates New Zealand, Fertility Plus, Repromed)

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Financial overview
9.5.4. Market share
9.5.5. Strategic moves and developments

10. SOUTH-EAST ASIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.1. Number of Cycles by Hospitals/Clinics
10.2. Market by End User

10.2.1. Fertility clinics
10.2.2. Hospitals
10.2.3. Surgical centers
10.2.4. Banks
10.2.5. Clinical research institutes

10.3. Regulatory issues, legislations and authorities
10.4. Insurance reimbursement scenario

 10.5. SINGAPORE IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.5.1. Number of Cycles by Hospitals/Clinics
10.5.2. Market by End User

10.5.2.1. Fertility clinics
10.5.2.2. Hospitals
10.5.2.3. Surgical centers
10.5.2.4. Banks
 10.5.2.5. Clinical research institutes

10.5.3. Regulatory issues, legislations and authorities
10.5.4. Insurance reimbursement scenario
10.5.5. Profiles of Major Players (NUH IVF Centre, Thomson Fertility Centre, Mount Elizabeth Fertility Center, Parkview Fertility Centre, Raffles Fertility Centre)

10.5.5.1. Company overview
10.5.5.2. Company snapshot
10.5.5.3. Financial overview
10.5.5.4. Market share
10.5.5.5. Strategic moves and developments

 10.6. MALAYSIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.6.1. Number of Cycles by Hospitals/Clinics
10.6.2. Market by End User

10.6.2.1. Fertility clinics
10.6.2.2. Hospitals
10.6.2.3. Surgical centers
10.6.2.4. Banks
10.6.2.5. Clinical research institutes

10.6.3. Regulatory issues, legislations and authorities
10.6.4. Insurance reimbursement scenario
10.6.5. Profiles of Major Players (Subang Fertility Center Subang Jaya Hospital, TMC Fertility Center formerly known as Damansara Fertility center, Fertility Centre Scaudinavia, Concept Fertility Center (Malaysia), Medically Assisted Conception Centre)

10.6.5.1. Company overview
10.6.5.2. Company snapshot
10.6.5.3. Financial overview
10.6.5.4. Market share
10.6.5.5. Strategic moves and developments

 10.7. INDONESIA IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.7.1. Number of Cycles by Hospitals/Clinics
10.7.2. Market by End User

10.7.2.1. Fertility clinics
10.7.2.2. Hospitals
10.7.2.3. Surgical centers
10.7.2.4. Banks
10.7.2.5. Clinical research institutes

10.7.3. Regulatory issues, legislations and authorities
10.7.4. Insurance reimbursement scenario
10.7.5. Profiles of Major Players (Anugerah Fertility Center, Morula IVF, Fertility Centre, Siloam Hospitals Surabana, Aster Fertility Clinic, Yasmin IVF)

10.7.5.1. Company overview
10.7.5.2. Company snapshot
10.7.5.3. Financial overview
10.7.5.4. Market share
10.7.5.5. Strategic moves and developments

 10.8. PHILIPPINES IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.8.1. Number of Cycles by Hospitals/Clinics
10.8.2. Market by End User

10.8.2.1. Fertility clinics
10.8.2.2. Hospitals
10.8.2.3. Surgical centers
10.8.2.4. Banks
10.8.2.5. Clinical research institutes

10.8.3. Regulatory issues, legislations and authorities
10.8.4. Insurance reimbursement scenario
10.8.5. Profiles of Major Players (Center for Reproductive Medicine, Victory Art Lab, CRM-MIA-Philippines)

10.8.5.1. Company overview
10.8.5.2. Company snapshot
10.8.5.3. Financial overview
10.8.5.4. Market share
10.8.5.5. Strategic moves and developments

 10.9. THAILAND IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.9.1. Number of Cycles by Hospitals/Clinics
10.9.2. Market by End User

10.9.2.1. Fertility clinics
10.9.2.2. Hospitals
10.9.2.3. Surgical centers
10.9.2.4. Banks
10.9.2.5. Clinical research institutes

10.9.3. Regulatory issues, legislations and authorities
10.9.4. Insurance reimbursement scenario
10.9.5. Profiles of Major Players (Bangkok Fertility Center, Jetanin Institute for Assisted Reproduction, Perfect Woman Institute Piyavate Hospital, Ramathibodi Hosp, Mahidol University, Bangkok Thailand, Siriraj Hospital)

10.9.5.1. Company overview
10.9.5.2. Company snapshot
10.9.5.3. Financial overview
10.9.5.4. Market share
10.9.5.5. Strategic moves and developments

 10.10. VIETNAM IVF MARKET (REVENUE AND NUMBER OF CYCLES)

10.10.1. Number of Cycles by Hospitals/Clinics
10.10.2. Market by End User

10.10.2.1. Fertility clinics
10.10.2.2. Hospitals
10.10.2.3. Surgical centers
10.10.2.4. Banks
10.10.2.5. Clinical research institutes

10.10.3. Regulatory issues, legislations and authorities
10.10.4. Insurance reimbursement scenario
10.10.5. Profiles of Major Players (IVF Center of National Hospital of GB. Gyn, IVF Lab Tu Du Hospital Vietnam, IVF Van Hanh, IVFAS, Tu Du - Ho Chi Minh City Vietnam)

10.10.5.1. Company overview
10.10.5.2. Company snapshot
10.10.5.3. Financial overview
10.10.5.4. Market share
10.10.5.5. Strategic moves and developments

 

LIST OF TABLES
TABLE 1    ASIA PACIFIC IVF CYCLES BY COUNTRY, 2012 – 2020 (THOUSAND)
TABLE 2    ASIA PACIFIC IVF REVENUE BY COUNTRY, 2012 – 2020 ($MILLION)
TABLE 3    ASIA PACIFIC IVF CYCLES BY END USER, 2012 – 2020 (THOUSAND)
TABLE 4    ASIA PACIFIC IVF REVENUE BY END USER, 2012 – 2020 ($MILLION)
TABLE 5    THERMO FISHER SCIENTIFIC INC  BUSINESS OVERVIEW
TABLE 6    COMPANY SNAPSHOT
TABLE 7    EMD SERONO INC BUSINESS OVERVIEW
TABLE 8    COMPANY SNAPSHOT
TABLE 9    SUN PHARMACEUTICAL BUSINESS OVERVIEW
TABLE 10  COMPANY SNAPSHOT
TABLE 11  CADILA HEALTH CARE BUSINESS OVERVIEW
TABLE 12  COMPANY SNAPSHOT
TABLE 13  LG LIFE SCIENCE  BUSINESS OVERVIEW
TABLE 14  COMPANY SNAPSHOT
TABLE 15  CHINA IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 16  CHINA IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 17  COOK MEDICAL INC BUSINESS OVERVIEW
TABLE 18  COMPANY SNAPSHOT
TABLE 19  VETROLIFE AB INC BUSINESS OVERVIEW
TABLE 20  COMPANY SNAPSHOT
TABLE 21  INDIA IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 22  INDIA IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 23  SUN PHARMACEUTICAL BUSINESS OVERVIEW
TABLE 24  COMPANY SNAPSHOT
TABLE 25  TRIVECTOR ORIGIO SCIENTIFIC  BUSINESS OVERVIEW
TABLE 26  COMPANY SNAPSHOT
TABLE 27  LAB IVF ASIA BUSINESS OVERVIEW
TABLE 28  COMPANY SNAPSHOT
TABLE 29  LG LIFE SCIENCE  BUSINESS OVERVIEW
TABLE 30  COMPANY SNAPSHOT
TABLE 31  CADILA HEALTH CARE  BUSINESS OVERVIEW
TABLE 32  COMPANY SNAPSHOT
TABLE 33  KOREA IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 34  KOREA IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 35  NEW ZEALAND IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 36  NEW ZEALAND IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 37  AUSTRALIA IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 38  AUSTRALIA IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 39  GENEA BIOMEDX TECHNOLOGIES BUSINESS OVERVIEW
TABLE 40  COMPANY SNAPSHOT
TABLE 41  THERMO FISHER SCIENTIFIC INC  BUSINESS OVERVIEW
TABLE 42  COMPANY SNAPSHOT
TABLE 43  JAPAN IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 44  JAPAN IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 45  EMD SERONO INC BUSINESS OVERVIEW
TABLE 46  COMPANY SNAPSHOT
TABLE 47  BIRTH RATE OF SOUTH-EAST ASIA PER THOUSAND, 2012
TABLE 48  SOUTH-EAST ASIA IVF REVENUE BY END USERS, 2012 – 2013 ($MILLION)
TABLE 49  SOUTH-EAST ASIA IVF REVENUE BY COUNTRY, 2012 – 2013 ($MILLION)
TABLE 50  SOUTH-EAST ASIA IVF CYCLES BY COUNTRY, 2012 – 2013 (THOUSAND)
TABLE 51  SOUTH-EAST ASIA IVF CYCLES BY END USER, 2012 – 2013 (THOUSAND)
TABLE 52  SINGAPORE IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 53  SINGAPORE IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 54  PACIFIC HEALTHCARE  BUSINESS OVERVIEW
TABLE 55  COMPANY SNAPSHOT
TABLE 56  ESCO TECHNOLOGIES  BUSINESS OVERVIEW
TABLE 57  COMPANY SNAPSHOT
TABLE 58  EMD SERONO INC BUSINESS OVERVIEW
TABLE 59  COMPANY SNAPSHOT
TABLE 60  MALAYSIA IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 61  MALAYSIA IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 62  INDONESIA IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 63  INDONESIA IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 64  PHILIPPINES IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 65  PHILIPPINES IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 66  THAILAND IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 67  THAILAND IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)
TABLE 68  VIETNAM IVF REVENUE BY END USERS, 2012 – 2020 ($MILLION)
TABLE 69  VIETNAM IVF CYCLES BY END USERS, 2012 – 2020 (THOUSAND)

 


LIST OF FIGURES

FIG. 1   ASIA PACIFIC IVF MARKET BY COUNTRY, 2013 & 2020 ($MILLION)
FIG. 2   ASIA PACIFIC IVF MARKET BY END USERS, 2012 – 2020 ($MILLION)
FIG. 3  PERCENTAGE OF PEOPLE WHO PERCEIVED VARIOUS INFERTILITY REASONS (SINGAPORE, THAILAND, INDONESIA AND CHINA)
FIG. 4   CHINA FERTILITY RATE (CHILDREN BORN/WOMEN)
FIG. 5   TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN)
FIG. 6   TOTAL FERTILITY RATE (CHILDREN BORN/WOMEN) - SOUTH KOREA
FIG. 7   TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN)
FIG. 8   TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN)
FIG. 9   TOTAL FERTILITY RATE (CHILDREN BORN/ WOMEN)
FIG. 10  SINGAPORE FERTILITY RATE CHILD BORN/WOMEN
FIG. 11  MALAYSIA FERTILITY RATE CHILD BORN/WOMEN
FIG. 12  INDONESIA FERTILITY RATE CHILD BORN/WOMEN
FIG. 13  PHILIPPINES FERTILITY RATE CHILD BORN/WOMEN
FIG. 14  THAILAND FERTILITY RATE CHILD BORN/WOMEN
FIG. 15  VIETNAM FERTILITY RATE CHILD BORN/WOMEN

  

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Countries in Asia Pacific with such lower levels of fertility have initiated innovative assistance programs to promote parenthood and provide subsidies on fertility treatments such as IVF. In addition, lower treatment cost as compared to western countries has also proved to be encouraging for the artificial reproductive treatment (ART) industry in the region.

SIMILAR MARKET STUDIES

Published Reports

In vitro diagnostics (IVD) is the technique of diagnostic test outside the human body in an artificial environment. The IVD market revenue is expected to reach $74.65 billion by 2020, from the market value of $53.32 billion in 2013, at a CAGR of 5.34% during 2014-2020. The global IVD market is segmented based on techniques, product type, usability, application, end user and geography (North America, Europe, Asia Pacific and Rest of World). Geographically, Asia Pacific is the fastest growing region and very opportune market that would generate highest revenue by 2020. Increase in the number of chronic and infectious diseases, and technological advancements are the major driving factors for the market.
3 Jun 2014 | Price: $4515(SU) | View Details >>

The male infertility market is expected to grow to $301.5 million by 2020 with a CAGR of 4.9% during 2013-2020. Male infertility is defined as the inability of a male to impregnate his female partner after a year of unprotected intercourse. 20% of the total infertility is due to male factors. The major factors driving the male infertility market are the change in lifestyle, increasing age, environmental effects, etc., and these factors are majorly contributing to the rise in male infertility levels. The major limitation experienced in the male infertility market is due to repeated treatment failures leading to an emotional impact on the patient.
29 Apr 2014 | Price: $4515(SU) | View Details >>

In-vitro fertilization is a type of assisted reproductive technology that helps women in conceiving. The global IVF market was valued at $9.3 billion in 2012 and is expected to grow up to $21.6 billion by 2020. Delayed pregnancy in women is one of the major driving factors of the IVF market, as the chances of conceiving lowers with age. The pregnancy success rate with IVF technique is higher in the age group of 35-39.Globally, the number of couples with infertility issues was found to be 48.5 million in 2010.
29 Jan 2014 | Price: $4515(SU) | View Details >>

Traditional wound care & closure and advanced wound care & closure products are used to treat acute and chronic wounds. Chronic wounds are hard to heal wounds, which take substantial time to heal and are expensive to treat. Advanced wound care & closure products are emerging as a standard solution for treating chronic wounds.
22 Jul 2014 | Price: $4515(SU) | View Details >>

Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices that has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic cases.
17 Dec 2013 | Price: $4515(SU) | View Details >>

Upcoming Reports

Vital signs, such as breathing rate, temperature, heartbeat and blood pressure are essential in measuring, monitoring and keeping a watch on basic body functioning. Vital signs devices thus play an important role in maintaining health as they monitor various vital parameters. The vital signs monitoring market comprises of services and devices for emergency care and support. The inclination of patients towards treatment at home as opposed to hospitals in order to cut costs is a significant trend witnessed in this market
Price: $4515 | Pre Book Price: $5315 | View Details >>

Renal Denervation is a novel approach for the treatment of resistant hypertension. It is an invasive, endovascular catheter based procedure that involves the use of radiofrequency ablation. Several devices have been approved for this procedure. The incidence of hypertension has been increasing worldwide, despite the availability of effective anti-hypertensive medicines.
Price: $4515 | Pre Book Price: $5315 | View Details >>

Sports medicine is a branch of medicine that deals with the prevention and treatment of injuries incurred during sports activities, exercises or physical fitness training. Sports medicine devices therefore, include a wide range of products utilized for the prevention, recovery and cure of injuries related to the above physical activities. These injuries consist of fractures, sprains, soft tissue damage, joint dislocation, strain and musculoskeletal injuries.
Price: $4515 | Pre Book Price: $5315 | View Details >>

Spectrometry is an analytical technique that assists in the identification of compounds and elements. This identification is based on the measurement of radiant energy emitted by a substance when in a higher energy state. Spectrometry instruments play a vital role in the analytical, pharmaceutical and life science industry. These industries have witnessed a growing demand for spectrometric instruments as they form an integral part of basic research and are used in drug composition identification, identification of new compounds and metals and bimolecular analysis. Due to its significant applications in different industries,
Price: $4515 | Pre Book Price: $5315 | View Details >>

Medical gases are meant to be administered to a patient for therapeutic, diagnostic or anesthetic purposes. These gases have wide application in healthcare. They are produced, distributed and facilitated through means of medical gas equipment. The main driver for this market is the U.S. Food and Drug Administration Safety and Innovation Act, implemented in July 2012,that enables manufacturers to control costs and to file for intellectual property rights for new medical gas and equipment products.
Price: $4515 | Pre Book Price: $5315 | View Details >>
First time Buyer ?
Check offer and
discount on this report


Get Discount

NEED MORE INFORMATION?
Call
+1 617 674 4143


Purchase Enquiry

PURCHASE OPTIONS

Single User
By obtaining a Single User License, you and your organization concur that only an individual uses this report either electronically or online. The right to use or stockpiling of the report should be confined only to one authorized computer. User will have authorization to print one duplicate of the report for individual use, yet may not be replicated for circulation. Additional copies for this report may also be order at discounted price for use by addition readers/users.
$5315

Multi User 
Multi-User license permits you to access the report from eight authorized computers. It does not permit you to display it on your company website and permits you to only print 5 copies of the report that shall not be reproduced for circulation.
$8315

Corporate  
With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report in is prohibited without the prior permission of Allied Market Research. The publisher will, in turn, regard the privacy of the purchaser and will keep it confidential. Upon buying single or multi-user license, buyer must provide the names and email ids of the authorized users of this report.
$11315


Not Interested in buying complete report?
To check the cost of chapters

WHY ALLIED MARKET RESEARCH?
INFALLIBLE METHODOLOGY
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader






Top